Physician profile
Ryan Light
NPI 1912136946
$6,399.74
in general payments reported to CMS, 2019-2025
42 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $663 · 2021: $606 · 2022: $814 · 2023: $988 · 2024: $1,374 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,504.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,241.05 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,020.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $432.12 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $407.64 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $382.10 | 2019-2025 | Xarelto, Spravato |
| Abbott Laboratories | $338.99 | 2021-2025 | Freestyle Libre 3, Proclaim, Cardiomems |
| Lilly USA, LLC | $334.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $266.38 | 2020-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.69 | 2020-2025 | Jardiance |
| Pfizer INC. | $253.63 | 2019-2025 | |
| Amgen INC. | $198.10 | 2019-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $176.23 | 2020-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.84 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $128.09 | 2019-2021 | |
| Fidia Pharma USA INC. | $105.28 | 2022-2025 | Triluron |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Light listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.